Relief Therapeutics Holding AG (RLFTF)

[eastsidekid]

Why does it seem RLF-100 is being ignored? Is it because it focuses mainly on the respiratory failure element of the disease progression?

RLF-100 took someone off a ventilator in <4 days who was a double lung transplant with near respiratory failure from Covid-19. I work with medical writers who pointed out to me the need for a greater number of successes/trial participants than the dozen or so recently allowed to take it because they were otherwise inaccessible, i.e., could not be moved to trial site, too critical, etc.

Extending my question: this excerpt from RAPS.org 5 days ago -

"The US government has chosen three vaccine candidates to fund for Phase 3 trials under Operation Warp Speed: Moderna’s mRNA-1273, The University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech's BNT162. Members of ACTIV have suggested developing safe controlled human infection models (CHIMs) for human trials could take 1-2 years. "